NO20074639L - Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin - Google Patents

Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin

Info

Publication number
NO20074639L
NO20074639L NO20074639A NO20074639A NO20074639L NO 20074639 L NO20074639 L NO 20074639L NO 20074639 A NO20074639 A NO 20074639A NO 20074639 A NO20074639 A NO 20074639A NO 20074639 L NO20074639 L NO 20074639L
Authority
NO
Norway
Prior art keywords
phenylindan
dimethylpiperazine
chloro
trans
crystalline base
Prior art date
Application number
NO20074639A
Other languages
English (en)
Other versions
NO339863B1 (no
Inventor
Benny Bang-Andersen
Heidi Lopez De Diego
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074639(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20074639L publication Critical patent/NO20074639L/no
Publication of NO339863B1 publication Critical patent/NO339863B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Krystallinsk base av forbindelse trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin, fremgangsmåter for fremstillingen av renset fri base eller salter av denne forbindelse, farmasøytiske sammensetninger omfattende basen og medisinsk anvendelse derav, inklusive for behandling av schizofreni og andre psykotiske lidelser.
NO20074639A 2005-02-16 2007-09-12 Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin NO339863B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500239 2005-02-16
PCT/DK2006/000088 WO2006086986A1 (en) 2005-02-16 2006-02-14 Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Publications (2)

Publication Number Publication Date
NO20074639L true NO20074639L (no) 2007-09-12
NO339863B1 NO339863B1 (no) 2017-02-13

Family

ID=37908539

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074639A NO339863B1 (no) 2005-02-16 2007-09-12 Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin

Country Status (28)

Country Link
US (2) US7648991B2 (no)
EP (1) EP1853576B1 (no)
JP (1) JP5055135B2 (no)
KR (1) KR101386387B1 (no)
CN (1) CN101119983B (no)
AR (1) AR052909A1 (no)
AT (1) ATE515501T1 (no)
AU (1) AU2006215957B9 (no)
BR (1) BRPI0607436B8 (no)
CA (1) CA2597622C (no)
CY (1) CY1111857T1 (no)
DK (1) DK1853576T3 (no)
EA (1) EA017631B1 (no)
ES (1) ES2368786T3 (no)
HR (1) HRP20110645T1 (no)
IL (1) IL184551A (no)
MX (1) MX2007009980A (no)
MY (1) MY148683A (no)
NO (1) NO339863B1 (no)
NZ (1) NZ556397A (no)
PL (1) PL1853576T3 (no)
PT (1) PT1853576E (no)
RS (1) RS51944B (no)
SI (1) SI1853576T1 (no)
TW (1) TWI376373B (no)
UA (1) UA95901C2 (no)
WO (1) WO2006086986A1 (no)
ZA (1) ZA200705982B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1658277T3 (pl) 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) * 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
CN102065861B (zh) * 2008-05-07 2013-10-16 H.隆德贝克有限公司 反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途
CN102170884A (zh) * 2008-10-03 2011-08-31 H.隆德贝克有限公司 口服制剂
DK2720989T3 (en) 2011-06-20 2016-11-28 H Lundbeck As Deuterated 1-piperazino-3-phenyl-indanes used to treat schizophrenia
WO2020089147A1 (en) 2018-10-29 2020-05-07 H. Lundbeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
HUT67665A (en) 1991-11-05 1995-04-28 Smithkline Beckman Corp Indane and indene deriv.s as endothelin receptor antagonists, pharmaceutical compn.s contg. them and process for prepg. them
CA2091204C (en) 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
JPH06184132A (ja) 1992-12-22 1994-07-05 Kotobuki Seiyaku Kk ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤
ES2108484T3 (es) 1993-11-30 1997-12-16 Pfizer Procedimiento para la preparacion de una tetralona asimetrica.
CA2132411A1 (en) 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6455736B1 (en) 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US5807897A (en) 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
ATE255555T1 (de) 1998-05-01 2003-12-15 Pfizer Prod Inc Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie
KR100605140B1 (ko) 1998-05-22 2006-07-28 싸이오스 인크 심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법
DE19824470A1 (de) 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
FR2786769B1 (fr) 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
JP2000351773A (ja) 1999-06-08 2000-12-19 Yamanouchi Pharmaceut Co Ltd フラン誘導体からなる医薬
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
IN187170B (no) 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
PL1658277T3 (pl) * 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
WO2006086985A1 (en) 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound

Also Published As

Publication number Publication date
MY148683A (en) 2013-05-31
ZA200705982B (en) 2009-06-24
AU2006215957B2 (en) 2011-09-29
KR101386387B1 (ko) 2014-04-25
HK1117525A1 (en) 2009-01-16
CN101119983A (zh) 2008-02-06
SI1853576T1 (sl) 2011-11-30
US20080153848A1 (en) 2008-06-26
AR052909A1 (es) 2007-04-11
PL1853576T3 (pl) 2011-12-30
JP5055135B2 (ja) 2012-10-24
BRPI0607436A2 (pt) 2010-04-06
AU2006215957B9 (en) 2012-02-16
EA200701740A1 (ru) 2007-12-28
EP1853576B1 (en) 2011-07-06
US20100105699A1 (en) 2010-04-29
EP1853576A1 (en) 2007-11-14
AU2006215957A1 (en) 2006-08-24
BRPI0607436B1 (pt) 2020-10-06
HRP20110645T1 (hr) 2011-10-31
CA2597622C (en) 2013-11-12
NZ556397A (en) 2010-06-25
KR20070103414A (ko) 2007-10-23
WO2006086986A1 (en) 2006-08-24
CN101119983B (zh) 2014-11-12
UA95901C2 (en) 2011-09-26
IL184551A0 (en) 2007-10-31
IL184551A (en) 2014-05-28
NO339863B1 (no) 2017-02-13
EA017631B1 (ru) 2013-02-28
ES2368786T3 (es) 2011-11-22
TW200640890A (en) 2006-12-01
ATE515501T1 (de) 2011-07-15
US8450324B2 (en) 2013-05-28
DK1853576T3 (da) 2011-09-26
PT1853576E (pt) 2011-09-28
TWI376373B (en) 2012-11-11
JP2008530040A (ja) 2008-08-07
CY1111857T1 (el) 2015-11-04
BRPI0607436B8 (pt) 2021-05-25
RS51944B (sr) 2012-02-29
US7648991B2 (en) 2010-01-19
MX2007009980A (es) 2007-09-26
CA2597622A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
NO20074639L (no) Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
NO20061153L (no) Trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
NO20045589L (no) Nye forbindelser
NO20056130L (no) Nye substituerte 3-svovelindoler
NO20055219L (no) Nye forbindelser
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
NO20070855L (no) Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
NO20060870L (no) Fluorsubstituert omega-karboksyaryldifenylurea for behandling og profylakse av sykdommer og tilstander
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
SE0401762D0 (sv) Novel compounds
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
NO20083751L (no) Metoder for behandling av kognitive og andre sykdommer
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

MM1K Lapsed by not paying the annual fees